u/bilal_osei

This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.

The sulphur burps profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

Cosigning. The appetite change and the scale change ran about three weeks apart for me too.

nausea that arrives on day two and fades by day four is the standard shape

preclinical is not clinical and rodents are not small people

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

My stall was eleven weeks. Eleven. Then it moved again without me changing anything at all.

ask what the beyond-use date is based on

Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.

Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

the TRIUMPH programme is still running, so anything definitive is premature

trialwatch_theo is right about the escalation being the variable. It explains most of the difficult reports here.

small trial, big effect, wide error bars

Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.

the pharmacy and the prescriber are two separate questions

comparing reta phase 2 to sema phase 3 is comparing different things

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

do not chase somebody else’s titration schedule, they are not you

What concentration is on the label, and does it match what you were expecting?

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

Yes. Week 9 is when almost everybody writes the "is it still working" post, and almost everybody is fine.

do not chase somebody else’s titration schedule, they are not you

the glucagon component is why the metabolic story reads differently

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

Who is the prescriber, and are they the same organisation as the pharmacy?

compounded is not generic, there is no equivalence claim

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

Disagree — a 503B being registered does not make its preparations equivalent to an approved product.

Agreed — and the follow-up question is what the beyond-use date is based on.

a mechanism you can state is not a mechanism you have demonstrated

Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation.

liver_enzyme_liz is right about the escalation being the variable. It explains most of the difficult reports here.

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

the ladder exists because the gut needs the time, not because the pharmacy likes paperwork

Does constipation track the day after the shot, or is it there all week?

sema is weekly for a reason, the half-life does the smoothing

Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.

Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.